GlassScriptPhysician profile
Sean M Karp
NPI 1326175837
$4,538.93
in general payments reported to CMS, 2019-2025
35 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $84.15 · 2021: $373 · 2022: $208 · 2023: $688 · 2024: $1,398 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525 · Education: $15.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.42 |
| Education | $15.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.19 | 2019-2025 | |
| Janssen Biotech, INC. | $434.06 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $326.96 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $259.51 | 2023-2025 | |
| Madrigal Pharmaceuticals | $253.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $253.53 | 2022-2024 | Zeposia |
| Genzyme Corporation | $246.04 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $224.15 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $221.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.82 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Medtronic, INC. | $150.06 | 2021 | |
| Boston Scientific Corporation | $116.52 | 2024 | Resolution Clip |
| Intercept Pharmaceuticals, INC. | $107.42 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $100.53 | 2019-2022 | |
| Qol Medical, LLC | $97.92 | 2025 | Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $97.40 | 2019 | |
| Redhill Biopharma INC. | $88.54 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $75.92 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $66.34 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $60.02 | 2024 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $45.99 | 2024 | Fujifilm |
| Evoke Pharma, INC. | $42.10 | 2021-2025 | |
| Celltrion USA INC. | $41.17 | 2024 | Zymfentra |
| Orphalan INC | $41.07 | 2025 | Cuvrior |
| Allergan, INC. | $33.75 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $33.29 | 2024-2025 | Givlaari |
| Merck Sharp & Dohme LLC | $29.38 | 2023-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $23.74 | 2024 | Ibsrela |
| Novo Nordisk INC | $22.58 | 2025 | Wegovy |
| Laborie Medical Technologies Corp. | $22.13 | 2023 | |
| Ucb, INC. | $20.55 | 2019 | |
| Braintree Laboratories, INC. | $19.98 | 2023 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $17.86 | 2022 | |
| Aimmune Therapeutics, INC. | $15.80 | 2024 | |
| Capsovision, INC. | $13.49 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Karp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.